INmune Bio Plans Phase 2 Alzheimer’s Trial Data Release Monday

INmune Bio Inc., a clinical-stage biotechnology company, is set to announce top-line results from its Phase 2 MINDFuL trial evaluating XPro™, a next-generation inhibitor of tumor necrosis factor, in patients with early Alzheimer's disease characterized by biomarkers of neuroinflammation. The trial includes individuals with mild cognitive impairment and mild Alzheimer's disease who received XPro or placebo over six months, with primary cognitive endpoints measured by EMACC and CDR assessments. The company will present the data during a conference call on June 30, 2025, at 8:00 AM EDT, accessible via phone and webcast, with a replay available through July 30. XPro acts by neutralizing soluble TNF without affecting trans-membrane TNF or its receptors and is administered once weekly via subcutaneous injection. Despite INmune Bio's promising therapeutic focus and analyst optimism, the company faces financial challenges, including declining revenue and ongoing losses, although it maintains a strong cash position relative to debt. The outcome of this trial could significantly impact INmune Bio's positioning in the biotechnology sector, especially in neurodegenerative disease treatment development.